造血干细胞移植治疗25例恶性血液病临床研究  

Hematopoietic stem cell transplantation for hematological malignancies

作　　者：钟美佐[1] 陈方平[1] 舒毅刚[1] 郑衡[1] 徐雅靖[1] 何群[1] 阳红斌[1] 

机构地区：[1]中南大学湘雅医院血液科,长沙410008

出　　处：《湖南医科大学学报》2002年第3期242-244,共3页Bulletin of Hunan Medical University

基　　金：湖南省生命科学重点项目(990 2 )

摘　　要：目的 :探讨造血干细胞移植治疗恶性血液病的疗效。方法 :分别对 2 5例恶性血液病患者进行自体骨髓移植、自体外周血干细胞移植或异基因外周血造血干细胞移植。对 8例自体造血干细胞移植的急性白血病患者坚持定期化疗。结果 :2 5例患者均获造血重建 ,随访 6～ 91月 ,5例死亡 ,2 0例仍长期无病生存。结论 :急性白血病患者自体造血干细胞移植后仍坚持定期化疗 ,可使其移植后复发率明显降低。造血干细胞移植是目前治疗恶性血液病的最佳手段之一。Objective To evaluate the efficacy of hematopoietic stem cell transplantation (HSCT) in hematological malignancies. Methods Twenty five patients with hematological malignancies were treated by autologous bone marrow transplantation (ABMT), autologous peripheral blood stem cell transplantation (APBSCT) or Allo PBSCT. Eight acute myeloid leuekmia (AML) patients who received autologous hematopoietic stem cell transplantation (AHSCT) were treated by chemotherapy again. Results All the patients engrafted gained hematopoietic reconstitution; they were followed up for 6 to 91 months; five patients died; twenty patients were alive in a disease free situation. Conclusion After the patients with acute leukemia receive AHSCT, the relapse incidences can be reduced obviously by regular chemotherapy. HSCT is one of the best methods for hematological malignancies.

关 键 词：造血干细胞移植 治疗 恶性血液病 临床研究 

分 类 号：R730.5[医药卫生—肿瘤]